Sight Sciences, INC 8-K filings

Sight Sciences, Inc. announced the appointment of Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, alongside the departure of Jeremy Hayden.

Sight Sciences, Inc. announced the successful election of two directors and the ratification of its independent auditor at its 2026 annual meeting.

Sight Sciences secured a $55.4 million judgment in a patent infringement lawsuit against Alcon concerning Alcon's Hydrus Microstent.

A Delaware court preserved Sight Sciences’ willful infringement verdict against Alcon, awarding $34M plus interest and a 10% Hydrus royalty through November 2028.

Sight Sciences reported a return to growth in Q4 2025, driven by Interventional Glaucoma, and initiated positive revenue guidance for 2026.

Sight Sciences, Inc. announced a 26-month extension for its Menlo Park headquarters lease, including a two-month rent abatement period.

Sight Sciences announced preliminary unaudited financial highlights for Q4 and full year 2025, showing strong Q4 revenue growth but a full-year decline.

Sight Sciences reports Q3 2025 financial results, raises full-year revenue guidance, and announces key executive and board appointments.

Sight Sciences announced that two Medicare Administrative Contractors established jurisdiction-wide pricing for its TearCare dry eye procedure, covering 10.4 million lives.

Sight Sciences, Inc. secured a six-month extension of its interest-only loan period with Hercules Capital, Inc. and reallocated an undrawn $10 million tranche, maintaining a $65 million credit facility.

Sight Sciences, Inc. announced a significant restructuring plan, including a 20% workforce reduction and revised operating expense guidance, to achieve long-term profitable growth without additional equity capital.

Sight Sciences reported second-quarter 2025 financial results, including an 8% revenue decrease, but raised its full-year 2025 revenue guidance and reaffirmed adjusted operating expense guidance.

Sight Sciences, Inc. announced the successful election of three Class I directors and the ratification of Deloitte & Touche LLP as its independent auditor at its annual stockholders' meeting held on June 5, 2025.

Sight Sciences announced its Q1 2025 financial results, reporting a revenue decrease of 9% compared to the prior year, while reaffirming its full-year 2025 revenue guidance and improving adjusted operating expenses guidance.

Sight Sciences appoints Gerhard (Gary) F. Burbach to its Board of Directors, effective April 21, 2025.

Sight Sciences announces its Q4 and full-year 2024 financial results, showing slight revenue growth for the quarter but a decrease for the year, and initiates 2025 financial guidance reflecting expected impacts from Medicare LCDs.

Sight Sciences' Compensation Committee approves annual base salaries and target cash incentive bonus opportunities for key executives for the fiscal year ending December 31, 2025.

Sight Sciences reports preliminary unaudited financial results for Q4 and full year 2024, showing mixed performance with growth in surgical glaucoma offset by a decline in dry eye revenue.

Sight Sciences has drawn down a $5 million loan tranche and issued warrants to lenders as part of a larger financing agreement.

Sight Sciences reported a slight revenue increase for Q3 2024, appointed a new COO, and updated its full-year adjusted operating expense guidance.

Sight Sciences has received confirmation of Medicare coverage for procedures using its OMNI and SION surgical systems, with some limitations on combined procedures.

Sight Sciences has received confirmation of Medicare coverage for procedures using its OMNI and SION surgical systems in 16 states and territories, with some limitations on combined procedures.

Sight Sciences reported a decrease in year-over-year revenue for the second quarter of 2024, while narrowing its full-year financial guidance due to a strategic shift in its Dry Eye business.

Sight Sciences held its annual meeting on June 6, 2024, electing three Class III directors and ratifying the appointment of Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2024.

Five Medicare Administrative Contractors have proposed draft coverage policies that, if enacted, could impact coverage for certain glaucoma procedures performed with Sight Sciences' OMNI and SION surgical systems.

Sight Sciences announced a 2% increase in first-quarter revenue to $19.3 million, alongside a reaffirmed full-year financial guidance and a positive jury verdict in a patent infringement case.

Sight Sciences secured a $34 million jury verdict against Alcon for patent infringement related to Alcon's Hydrus Microstent.

Sight Sciences announced its Q4 and full year 2023 financial results, showing a decrease in Q4 revenue but an overall increase for the year, and provided 2024 financial guidance.

Sight Sciences has disclosed the approved base salaries and cash incentive bonus opportunities for its top executives for the fiscal year 2024.

Sight Sciences has closed a new senior secured credit facility with Hercules Capital for up to $65 million, immediately drawing $35 million to refinance existing debt and enhance financial flexibility.